Mitomycin Medac

Mitomycin, the active ingredient in Mitomycin Medac, is an antineoplastic antibiotic presented as a sterile solution for intravesical use. It treats non‑muscle invasive bladder cancer in patients who require bladder‑preserving therapy after tumor resection.

GNH USA supplies Mitomycin Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mitomycin Medac is used in the intravesical management of urothelial malignancies, acting directly on bladder tumor cells to reduce recurrence.

- Non‑muscle invasive bladder cancer: provides intravesical chemotherapy to lower recurrence after transurethral resection. - Bladder carcinoma in situ: used to eradicate residual disease when surgical options are limited. - Recurrent urothelial carcinoma: administered as adjunctive intravesical therapy to improve disease‑free intervals.

Mitomycin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Bladder irritation: dysuria, urgency, or mild hematuria. - Nausea: transient gastrointestinal upset. - Low‑grade fever: mild, self‑limited temperature elevation.

Serious or Rare Side Effects: - Hemorrhagic cystitis: severe bladder bleeding requiring medical intervention. - Bone marrow suppression: neutropenia, anemia, or thrombocytopenia. - Allergic reaction: rash, pruritus, or anaphylaxis. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Renal impairment: acute kidney injury in susceptible patients.

Mitomycin requires careful monitoring and specific handling to minimise risks.

- Blood counts: monitor complete blood count regularly for signs of myelosuppression. - Renal function: assess serum creatinine and urine output before and during therapy. - Concomitant nephrotoxins: avoid or adjust dose when used with other renal‑toxic agents. - Catheter technique: ensure sterile insertion and proper bladder drainage to reduce infection risk. - Storage: Store at controlled room temperature: keep in original container, protect from light and moisture.

Mitomycin may interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Other myelosuppressive chemotherapy: increased risk of severe bone marrow suppression. - Pelvic radiation therapy: heightened bladder and tissue toxicity. - Nephrotoxic drugs (e.g., cisplatin): amplified renal damage.

Moderate Interactions (Monitor Closely): - Aminoglycoside antibiotics: monitor renal function closely. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate renal impairment. - Anticoagulants (e.g., warfarin): potential enhancement of bleeding risk.